Yahoo Finance

Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with ...

— REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate pozdeutinurad's efficacy in lowering serum urate (sUA) levels and resolution of target tophi in gout patients — SAN DIEGO, July 1, ...
Yahoo Finance

Arthrosi Announces First Patient Dosed in Replicate Pivotal Phase 3 REDUCE 1 Trial of Lead Compound AR882

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Contract Pharma

SOBI Agrees to Acquire Arthrosi Therapeutics

SOBI has agreed to acquire Arthrosi Therapeutics Inc., a late-stage biotechnology company developing a highly potent and ...
Morningstar

Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Pharmabiz

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...
Longview News-Journal

Arthrosi Announces First Patient Dosed in Replicate Pivotal Phase 3 REDUCE 1 Trial of Lead Compound AR882

— REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate AR882's efficacy in lowering serum urate (sUA) levels in gout patients — SAN DIEGO, March 17, 2025 /PRNewswire/ -- Arthrosi ...